

TRACER (S1415CD) NEWSLETTER



CANCER
RESEARCH
NETWORK



June 2019

STUDY UPDATES

- ✦ As of 6/10/2019, there are **3,094 patients registered** to study.
- ✦ Please note that **it is acceptable to prescribe biosimilar CSFs** for patients enrolled in this study.

THANK YOU TO OUR TOP ACCRUERS

CONGRATULATIONS TO CHI HEALTH SAINT FRANCIS, SANFORD MEDICAL CENTER, AND MULTICARE TACOMA GENERAL HOSPITAL FOR REACHING 100% ACCRUAL

CONGRATULATIONS TO OUR TOP ACCRUERS FOR THE MONTH OF MAY

- ★ **Geisinger Medical Center in Danville, PA (12 accruals)**
- ★ **Marshfield Clinic in Marshfield, WI (10 accruals)**
- ★ **Presbyterian Kaseman Hospital in Albuquerque, NM (9 accruals)**
- ★ **Doctors' Cancer Center in Manatí, PR (9 accruals)**

REMINDERS FOR SITES

Data Submission

Prior to registration, verify the febrile neutropenia risk level in Section 18.1 for the regimen the patient is planning to take. This is reported in OPEN at the time of registration.

When a patient discontinues the regimen under which they were registered (the one specified at registration from Section 18.1), submit the S1415CD Treatment Discontinuation form (Section 14.x).

Rave Quirks

Prior to deactivating a log line in Rave, all queries associated with that log line should be resolved; any unresolved queries will remain on the Rave reports. Please contact the Data Coordinator prior to deactivating a log line with open queries.


Protocol Notes

Section 18.1, Table 3, Colorectal Cancer Regimens, has an unfortunate line break across pages 56 and 57 in the protocol. The colorectal cancer regimen description for "Simplified biweekly infusional fluorouracil/leucovorin + bevacizumab" is across two different pages. We will correct this in a future revision.


TrACER: A Pragmatic Trial Assessing CSF Prescribing Effectiveness and Risk

This pragmatic trial is designed to test an intervention to increase compliance with guidelines, and generate evidence to assess effectiveness of Primary Prophylactic CSF (PP-CSF) on reducing rates of FN for patients receiving intermediate-risk chemotherapy regimens. TrACER is the first trial of its kind and is sponsored by SWOG, a part of the National Clinical Trials Network. The trial is led by Dr. Scott Ramsey at HICOR and funded in part by PCORI.

TrACER Total Accrual as of June 10, 2019



TrACER Accrual in the Past 12 Months



Contact Us

Site Requirements, including regimen questions: HICOR ▪ TrACER@fredhutch.org ▪ 206-667-7624
 Patient eligibility, study procedures, and data submission:
 SWOG SDMC ▪ cancercontrolquestion@crab.org ▪ 206-652-2267